{"id":55541,"date":"2026-01-26T21:56:59","date_gmt":"2026-01-26T13:56:59","guid":{"rendered":"https:\/\/flcube.com\/?p=55541"},"modified":"2026-01-26T21:57:00","modified_gmt":"2026-01-26T13:57:00","slug":"ascletis-doses-first-patient-in-us-phase-ii-diabetes-study-for-oral-glp-1-asc30","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55541","title":{"rendered":"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30"},"content":{"rendered":"\n<p><strong>Ascletis Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG:\u202f1672<\/a>) announced that the first patient has been dosed in a <strong>13\u2011week US Phase\u202fII study (NCT07321678)<\/strong> evaluating <strong>ASC30<\/strong>, an <strong>oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist<\/strong>, for the treatment of <strong>type\u202f2 diabetes<\/strong>. Topline results are expected in the <strong>third quarter of 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ascletis Pharma Inc. (HKEX:\u202f1672)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>ASC30 (small molecule GLP\u20111R full biased agonist)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase\u202fII (NCT07321678)<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>United States<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type\u202f2 diabetes<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>13 weeks<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Mean change in HbA1c at week\u202f13 vs. placebo<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Fasting plasma glucose, body weight, safety\/tolerability<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>First patient dosed<\/td><\/tr><tr><td><strong>Data Readout<\/strong><\/td><td>Q3\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>First and only small molecule GLP\u20111R full biased agonist<\/strong> in clinical development; activates GLP\u20111 receptor to enhance insulin secretion, suppress glucagon, and reduce appetite<\/li>\n\n\n\n<li><strong>Administration Flexibility:<\/strong> Designed for <strong>once\u2011daily oral dosing<\/strong> OR <strong>once\u2011monthly to once\u2011quarterly subcutaneous injection<\/strong>, offering patient choice between convenience and injection frequency<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Unlike peptide\u2011based GLP\u20111 agonists (semaglutide, tirzepatide), ASC30 is a <strong>small molecule<\/strong> with potential for <strong>lower manufacturing costs<\/strong> and <strong>improved stability<\/strong><\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Recently completed <strong>13\u2011week Phase\u202fII obesity study (NCT07002905)<\/strong> demonstrated <strong>statistically significant, dose\u2011dependent weight reduction<\/strong> with favorable safety profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-ii-obesity-study-nct07002905\">Clinical Evidence \u2013 Phase\u202fII Obesity Study (NCT07002905)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>ASC30 Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Weight Reduction<\/strong><\/td><td>Statistically significant, dose\u2011dependent<\/td><td>Validates GLP\u20111 mechanism in obesity<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable tolerability<\/td><td>Supports progression to diabetes study<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Oral and injectable versions<\/td><td>Demonstrates administration flexibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global GLP\u20111 Market (Diabetes)<\/strong><\/td><td>$42\u202fbillion<\/td><td>$52\u202fbillion<\/td><td>$65\u202fbillion<\/td><\/tr><tr><td><strong>Oral GLP\u20111 Share<\/strong><\/td><td>15\u202f%<\/td><td>18\u202f%<\/td><td>22\u202f%<\/td><\/tr><tr><td><strong>ASC30 Market Penetration (if approved)<\/strong><\/td><td>0\u202f%<\/td><td>0.5\u202f%<\/td><td>2\u202f%<\/td><\/tr><tr><td><strong>Annual Cost (Oral)<\/strong><\/td><td>\u2013<\/td><td>$8,000<\/td><td>$7,500<\/td><\/tr><tr><td><strong>Ascletis Revenue (ASC30)<\/strong><\/td><td>\u2013<\/td><td>$45\u202fmillion<\/td><td>$180\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rybelsus<\/strong> (oral semaglutide, Novo Nordisk) \u2013 Market leader, peptide\u2011based, daily dosing<\/li>\n\n\n\n<li><strong>Orforglipron<\/strong> (oral small molecule, Eli Lilly) \u2013 Phase\u202fIII, once\u2011daily<\/li>\n\n\n\n<li><strong>ASC30<\/strong> \u2013 <strong>First full biased agonist<\/strong> with <strong>flexible dosing<\/strong> (daily oral OR monthly\/quarterly injectable)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Ascletis\u2019 <strong>Hangzhou facility<\/strong> (cGMP certified) will produce clinical supply; small molecule synthesis offers <strong>cost advantage<\/strong> over biologics<\/li>\n\n\n\n<li><strong>Clinical Speed:<\/strong> Concurrent obesity and diabetes Phase\u202fII programs accelerate <strong>indication expansion<\/strong>; <strong>Phase\u202fIII initiation<\/strong> planned for 2027 pending data<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> US Phase\u202fII positions ASC30 for <strong>FDA fast\u2011track<\/strong>; <strong>China IND<\/strong> filing planned for Q2\u202f2026<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> Existing <strong>hepatitis C sales force<\/strong> (300 reps) can be leveraged for metabolic disease launch in China<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for ASC30. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012600060_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026012600060_c.\"><\/object><a id=\"wp-block-file--media-2ff5ffa2-b3e4-439b-b0b2-deed288e3c3d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012600060_c-1.pdf\">2026012600060_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026012600060_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2ff5ffa2-b3e4-439b-b0b2-deed288e3c3d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[189,62,980,4361],"class_list":["post-55541","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascletis-pharma","tag-clinical-trial-approval-initiation","tag-hkg-1672","tag-hot-targets"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week US Phase\u202fII study (NCT07321678) evaluating ASC30, an oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist, for the treatment of type\u202f2 diabetes. Topline results are expected in the third quarter of 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55541\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week US Phase\u202fII study (NCT07321678) evaluating ASC30, an oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist, for the treatment of type\u202f2 diabetes. Topline results are expected in the third quarter of 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55541\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:56:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T13:57:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55541#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55541\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30\",\"datePublished\":\"2026-01-26T13:56:59+00:00\",\"dateModified\":\"2026-01-26T13:57:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55541\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1672\",\"Hot targets\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55541#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55541\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55541\",\"name\":\"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T13:56:59+00:00\",\"dateModified\":\"2026-01-26T13:57:00+00:00\",\"description\":\"Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week US Phase\u202fII study (NCT07321678) evaluating ASC30, an oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist, for the treatment of type\u202f2 diabetes. Topline results are expected in the third quarter of 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55541#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55541\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55541#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30 - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week US Phase\u202fII study (NCT07321678) evaluating ASC30, an oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist, for the treatment of type\u202f2 diabetes. Topline results are expected in the third quarter of 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55541","og_locale":"en_US","og_type":"article","og_title":"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30","og_description":"Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week US Phase\u202fII study (NCT07321678) evaluating ASC30, an oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist, for the treatment of type\u202f2 diabetes. Topline results are expected in the third quarter of 2026.","og_url":"https:\/\/flcube.com\/?p=55541","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T13:56:59+00:00","article_modified_time":"2026-01-26T13:57:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55541#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55541"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30","datePublished":"2026-01-26T13:56:59+00:00","dateModified":"2026-01-26T13:57:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55541"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","Clinical trial approval \/ initiation","HKG: 1672","Hot targets"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55541#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55541","url":"https:\/\/flcube.com\/?p=55541","name":"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T13:56:59+00:00","dateModified":"2026-01-26T13:57:00+00:00","description":"Ascletis Pharma Inc. (HKG:\u202f1672) announced that the first patient has been dosed in a 13\u2011week US Phase\u202fII study (NCT07321678) evaluating ASC30, an oral small molecule GLP\u20111 receptor (GLP\u20111R) agonist, for the treatment of type\u202f2 diabetes. Topline results are expected in the third quarter of 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55541#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55541"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55541#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Doses First Patient in US Phase\u202fII Diabetes Study for Oral GLP\u20111 ASC30"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55541"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55541\/revisions"}],"predecessor-version":[{"id":55544,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55541\/revisions\/55544"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}